Please Wait.....
Report
Oncology Molecular Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026 - 2031)
Market Report I 2026-01-16 I 130 Pages I Mordor Intelligence
Oncology Molecular Diagnostics Market Analysis
Oncology Molecular Diagnostics Market size in 2026 is estimated at USD 4.13 billion, growing from 2025 value of USD 3.68 billion with 2031 projections showing USD 7.33 billion, growing at 12.18% CAGR over 2026-2031.
Companion diagnostics linked to targeted therapies, expanding liquid biopsy approvals, and AI-enabled bioinformatics are accelerating clinical uptake. Demand is also fueled by national genomics programs that improve reimbursement frameworks and by the rising prevalence of cancer, which drives multiple molecular tests per patient along the treatment continuum. Meanwhile, point-of-care platforms are moving sophisticated assays out of centralized laboratories, shrinking turnaround times and broadening access. Competitive dynamics favor vertically integrated leaders that pair proprietary reagents with analytics software, while niche innovators leverage AI and liquid biopsy technologies to capture white-space opportunities within the oncology molecular diagnostics market.
Global Oncology Molecular Diagnostics Market Trends and Insights
Liquid-biopsy companion diagnostics transforming treatment pathways
FDA approvals for liquid biopsy companion diagnostics have multiplied since 2023, enabling real-time genomic monitoring without invasive tissue sampling. FoundationOne Liquid CDx now guides MET exon 14 skipping therapy in non-small cell lung cancer, expanding precision care to patients with limited tissue. Clinical adoption is rising because the assays detect resistance mutations before imaging changes appear, letting oncologists switch therapies earlier and improving outcomes.
National genomics initiatives accelerating reimbursement frameworks
Programs such as Australia's PrOSPeCT offer 23,000 patients free genomic testing funded by USD 185 million, demonstrating how coordinated policy, clinical trial access, and coverage decisions converge to democratize precision oncology. As similar schemes roll out in China and Japan, standardized protocols lower payer uncertainty, expanding compensated testing indications across the oncology molecular diagnostics market.
Genomic pathologist shortage creating diagnostic bottlenecks
Only 3% of pathology departments report adequate staffing of genomic specialists, with Latin America most affected. Limited expertise constrains report interpretation and delays clinical decision making. Teleconsultation networks and AI decision support mitigate but do not fully resolve the capacity gap, tempering growth in regions with the greatest need.
Other drivers and restraints analyzed in the detailed report include:
AI-driven bioinformatics slashing NGS turnaround timesIncreasing demand for point-of-care testingCost barriers limiting adoption in emerging markets
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Reagents and consumables generated 61.55% revenue in 2025, reflecting recurrent demand and proprietary chemistries that capture low-abundance mutations. This strong position anchors steady cash flows for manufacturers within the oncology molecular diagnostics market. Software and services, although smaller today, rise at a 15.21% CAGR as cloud-hosted analytics automate interpretation and reduce the need for scarce genomic pathologists.
Growth in AI-powered platforms positions bioinformatics as a strategic moat. Vendors bundling reagents with subscription-based interpretation tools secure end-to-end integration, fostering customer stickiness. The oncology molecular diagnostics software solutions market size is projected to expand markedly as laboratories seek efficiency gains and standardized reporting.
PCR delivered 34.62% revenue in 2025 as laboratories value its cost efficiency and reliability. Digital PCR further extends sensitivity for detecting rare variants in liquid biopsy. In parallel, next-generation sequencing enjoys a 13.5% CAGR, propelled by declining run costs and broader clinical utility. Hybrid capture panels detect hundreds of genes in one assay, transforming treatment selection.
NGS adoption also benefits from combined tissue and plasma workflows that reveal tumor heterogeneity. As laboratories validate liquid biopsy NGS panels, the oncology molecular diagnostics market size for comprehensive profiling grows faster than single-gene PCR assays, yet PCR remains indispensable for rapid single-mutation confirmation.
The Oncology Molecular Diagnostics Market Report is Segmented by Product Type (Instrument, and More), Technology (Polymerase Chain Reaction, and More), Cancer Type (Breast Cancer, and More), Sample Type (Tissue Biopsy, and More), End User (Hospitals, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America accounted for 39.72% revenue in 2025, leveraging early regulatory approvals and broad insurance coverage for comprehensive genomic profiling. Testing rates for actionable biomarkers approach 90% in leading cancer centers. Expanded Medicare coverage for minimal residual disease tracking further enlarges the oncology molecular diagnostics market.
Europe adopts a cost-effectiveness lens, leading to selective uptake but consistent reimbursement once clinical utility is proven. Harmonized companion diagnostic and drug approvals by the European Medicines Agency ensure synchronized market entry, supporting stable growth moderated by budget impact assessments.
Asia-Pacific posts the fastest 15.89% CAGR supported by China's precision medicine plan and Japan's genomic cancer program. Investments in national sequencing networks and public-private partnerships lower per-test costs and accelerate technology transfer. As local innovators refine assays for region-specific mutations, the oncology molecular diagnostics market size in Asia-Pacific expands rapidly with rising cancer incidence and improving healthcare infrastructure.
List of Companies Covered in this Report:
Abbott Laboratories Roche Danaher Thermo Fisher Scientific Illumina QIAGEN Sysmex bioMerieux Agilent Technologies Inc. (Dako) HTG Molecular Diagnostics Veracyte TBG Diagnostics Ltd. Guardant Health Foundation Medicine Inc. Exact Sciences Corp. NeoGenomics Laboratories BGI Genomics Co. Ltd. Bio-Rad Laboratories Natera Myriad Genetics
Additional Benefits:
The market estimate (ME) sheet in Excel format
3 months of analyst support
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Uptake of Liquid-Biopsy Companion Diagnostics Post FDA & EMA Approvals
4.2.2 National Genomics Initiatives Accelerating Reimbursement
4.2.3 AI-driven Bioinformatics Reducing NGS Turn-around Time
4.2.4 Rising Prevalence of Cancer
4.2.5 Increasing Demand for Point-of-care Testing
4.2.6 Growing Integration of Multi-Omics Approaches for Comprehensive Cancer Profiling
4.3 Market Restraints
4.3.1 Shortage of Genomic Pathologists in Latin America
4.3.2 High Cost of Molecular Diagnostic Tests
4.3.3 Sensitivity & QC Challenges in Liquid Biopsy ctDNA Testing
4.3.4 Lack of Skilled Workforce and Stringent Regulatory Framework
4.4 Regulatory Landscape
4.5 Porter's Five Forces Analysis
4.5.1 Bargaining Power of Buyers
4.5.2 Bargaining Power of Suppliers
4.5.3 Threat of New Entrants
4.5.4 Threat of Substitutes
4.5.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value in USD)
5.1 By Product Type
5.1.1 Instruments
5.1.2 Reagents & Consumables
5.1.3 Software & Services
5.2 By Technology
5.2.1 Polymerase Chain Reaction (PCR)
5.2.2 Isothermal NAAT
5.2.3 Next-Generation Sequencing (NGS)
5.2.4 In-situ Hybridization (FISH/CISH)
5.2.5 Mass Spectrometry
5.2.6 Chips & Microarrays
5.2.7 Transcription-Mediated Amplification
5.3 By Cancer Type
5.3.1 Breast Cancer
5.3.2 Lung Cancer
5.3.3 Colorectal Cancer
5.3.4 Prostate Cancer
5.3.5 Hematological Malignancies
5.3.6 Liver Cancer
5.3.7 Cervical & Gynecologic Cancers
5.3.8 Other Solid Tumors
5.4 By Sample Type
5.4.1 Tissue Biopsy
5.4.2 Liquid Biopsy (Blood/Plasma/Serum)
5.4.3 Fine-Needle Aspirates & Cytology Samples
5.5 By End User
5.5.1 Hospitals
5.5.2 Diagnostic Centers
5.5.3 Point-of-Care Settings
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 Japan
5.6.3.3 India
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Rest of Asia-Pacific
5.6.4 Middle East & Africa
5.6.4.1 GCC
5.6.4.2 South Africa
5.6.4.3 Rest of Middle East & Africa
5.6.5 South America
5.6.5.1 Brazil
5.6.5.2 Argentina
5.6.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Abbott Laboratories
6.3.2 F. Hoffmann-La Roche Ltd
6.3.3 Danaher Corporation
6.3.4 Thermo Fisher Scientific Inc.
6.3.5 Illumina Inc.
6.3.6 Qiagen N.V.
6.3.7 Sysmex Corporation
6.3.8 bioMerieux SA
6.3.9 Agilent Technologies Inc. (Dako)
6.3.10 HTG Molecular Diagnostics Inc.
6.3.11 Veracyte Inc.
6.3.12 TBG Diagnostics Ltd.
6.3.13 Guardant Health Inc.
6.3.14 Foundation Medicine Inc.
6.3.15 Exact Sciences Corp.
6.3.16 NeoGenomics Laboratories
6.3.17 BGI Genomics Co. Ltd.
6.3.18 Bio-Rad Laboratories Inc.
6.3.19 Natera Inc.
6.3.20 Myriad Genetics Inc.
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security